Call for greater investment and innovation from pharma to address RSV
Despite progress from AstraZeneca, Sanofi, Merck & Co, GSK and Pfizer, analysts say effective respiratory syncytial virus treatments are still needed.
List view / Grid view
Despite progress from AstraZeneca, Sanofi, Merck & Co, GSK and Pfizer, analysts say effective respiratory syncytial virus treatments are still needed.
Contract development and manufacturing services will be provided as Rezon Bio from Poland, with the biosimilars company operating from Switzerland.
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
The planned succession will also see him become Chair of the German pharma company’s Executive Board in May 2026.
The deal will support the biotech in its plans to advance bispecific antibody petosemtamab in multiple oncology indications.
In a surprise announcement, she will be replaced at the UK pharma company by its Chief Commercial Officer Luke Miels.
The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease.
Pharma manufacturing facility construction placed at the heart of a policy announcement made on social media.
As other pharma companies reconsider their investments, Moderna’s focus insulates it from the UK’s drug pricing row.
uniQure’s positive topline data “are the most convincing in the field to date” and indicate the gene therapy’s potential disease-modifying effects.
The innovative approach facilitates QSRR-assisted chromatographic development for N-nitrosamine analysis in pharmaceutical products.
The new $6.5 billion Houston site will manufacture active pharmaceutical ingredients (APIs) in support of the company’s pipeline of small molecule medicines.
Extends its digital transformation partnership with Siemens to make greater use of automation, data and AI in its services.
Advances cell therapy and gene therapy candidates, with both showing neurorestorative potential against the disease.
The deal with the US biopharma adds a portfolio of clinical-stage incretin and amylin research programmes to its pipeline.